eng URI http://hdl.handle.net/10795/2805 βιοτεχνολογία υγεία ποιότητα του προϊόντος ασθένεια ένζυμο Group VIA calcium-independent phospholipase A2 (GVIA iPLA2) has recently emerged as an important pharmaceutical target. Selective and potent GVIA iPLA2 inhibitors can be used to study its role in various neurological disorders. In the current work, we explore the significance of the introduction of a substituent in previously reported potent GVIA iPLA2 inhibitors. 1,1,1,2,2-Pentafluoro-7-(4-methoxyphenyl)heptan-3-one (GK187) is the most potent and selective GVIA iPLA2 inhibitor ever reported with a XI(50) value of 0.0001, and with no significant inhibition against GIVA cPLA2 or GV sPLA2. We also compare the inhibition of two difluoromethyl ketones on GVIA iPLA2, GIVA cPLA2, and GV sPLA2. 7 pp. LOMv1.0 creator LOMv1.0 publisher LOMv1.0 Project Final Beneficiary LOMv1.0 Project Executing Organisation 2013-07-16 Digital Library of the Operational Programme "Education and Lifelong Learning" abstract types Text Phospholipase A2 Inhibitor Νeurological disorders GVIA iPLA2 Polyfluoroalkyl ketone Pentafluoroethyl ketones irakleitos2.aua.gr/sites/default/files/ΔΗΜΟΣΙΕΥΣΗ_2013.pdf 549964 application/pdf http://repository.edulll.gr/edulll/bitstream/10795/2805/2/2805_Document-15.pdf URI http://hdl.handle.net/10795/2805 LOMv1.0creator 2016-04-21T10:32:17Z LOMv1.0validator 2016-04-21T10:32:17Z LOMv1.0 gre no no Copyright EYD-EPEDBM (Operational Programme "Education and Lifelong Learning")